Tag: inhibitor

Research discovers inhibitor to reverse toxic DUX4 effects

About one in 8,000 people have facioscapulohumeral muscular dystrophy, according to a 2014 study, which is relatively common in the world of genetic diseases. New University of Minnesota Medical School research identifies an inhibitor that protects cells from toxic effects associated with this disease in cells and mice. Facioscapulohumeral muscular dystrophy (FSHD) is a genetic

Phase 1 study shows novel KRAS inhibitor well tolerated by patients with adenocarcinoma and non-small cell lung cancer

A clinical trial testing the toxicity of a KRAS inhibitor demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation, according to research presented today at the IASLC 2019 World Conference on Lung Cancer, hosted by the International Association for the Study of

TYK2 Inhibitor Clears Psoriasis Over 12 Weeks

TUESDAY, Oct. 9, 2018 — Selective inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher results in greater clearing of psoriasis versus placebo over 12 weeks, according to a phase 2 study published in the Oct. 4 issue of the New England Journal of Medicine. Kim Papp, M.D.,

RB1 gene mutations underlie clinical resistance to CDK 4/6 inhibitor breast cancer therapy

A multi-institutional research team has identified what may be a novel mechanism underlying acquired resistance to CDK 4/6 inhibitor treatment for breast cancer. In their report published in the Annals of Oncology, the team—led by investigators at Massachusetts General Hospital (MGH), Institute Gustave Roussy in Paris, and Texas Oncology-Baylor Sammons Cancer Center/U.S. Oncology in Dallas—reports